H.R. 2666 · 118th Congress

Medicaid VBPs for Patients Act

Introduced on Apr 18, 2023 by Brett Guthrie (R-KY-2). 42 cosponsors, 20 of them from another party. Latest action (Dec 19, 2024): Placed on the Union Calendar, Calendar No. 768.

Stage
Reported by committee
Introduced
Apr 18, 2023
Cosponsors
42
20 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.

Subjects

  • Administrative law and regulatory procedures
  • Congressional oversight
  • Department of Health and Human Services
  • Government studies and investigations
  • Health care costs and insurance
  • Intergovernmental relations
  • Medicaid
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Brett GuthrieR-KY-2Sponsor

Democrats · 20

Republicans · 22

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Apr 18, 2023Introduced in House
  2. Apr 18, 2023Introduced in House
  3. Apr 18, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Apr 18, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. May 15, 2023 · HouseReferred to the Subcommittee on Health.
  6. May 17, 2023 · HouseSubcommittee Consideration and Mark-up Session Held.
  7. May 17, 2023 · HouseForwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11 .
  8. May 24, 2023 · HouseCommittee Consideration and Mark-up Session Held.
  9. May 24, 2023 · HouseOrdered to be Reported (Amended) by the Yeas and Nays: 31 - 19.
  10. Nov 18, 2024Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-743, Part I.
  11. Nov 18, 2024 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-743, Part I.
  12. Nov 18, 2024 · HouseHouse Committee on Ways and Means Granted an extension for further consideration ending not later than Dec. 19, 2024.
  13. Dec 17, 2024 · HouseReferred to the Subcommittee on Work and Welfare.
  14. Dec 19, 2024Committee on Ways and Means discharged.
  15. Dec 19, 2024 · HouseCommittee on Ways and Means discharged.
  16. Dec 19, 2024 · HousePlaced on the Union Calendar, Calendar No. 768.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ALLIANCE FOR REGENERATIVE MEDICINE14 reports
    $880K reported (all issues)
  2. SPARK THERAPEUTICS, INC.13 reports
    $1M reported (all issues)
  3. ACADEMY OF MANAGED CARE PHARMACY10 reports
    $660K reported (all issues)
  4. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA9 reports
    $37.4M reported (all issues)
  5. ORCHARD THERAPEUTICS NORTH AMERICA8 reports
    $360K reported (all issues)
  6. bluebird bio, Inc.8 reports
    $560K reported (all issues)
  7. PTC THERAPEUTICS, INC.6 reports
    $930K reported (all issues)
  8. AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)5 reports
    $14.2M reported (all issues)
  9. BIOMARIN PHARMACEUTICAL INC.5 reports
    $1.8M reported (all issues)
  10. CSL BEHRING5 reports
    Federal contractor: CSL BEHRING L.L.C.$663K in contracts, FY2026AI match · 100%
  11. California Hospital Association5 reports
    $2M reported (all issues)
  12. JOHNSON & JOHNSON SERVICES, INC.5 reports
  13. MERCK & CO., INC.5 reports
    $11.1M reported (all issues)Federal contractor: MERCK SHARP & DOHME LLC$445.3K in contracts, FY2026AI match · 100%
  14. NOVARTIS CORPORATION5 reports
    $6.9M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  15. The Cigna Group and subsidiaries (Formerly Cigna Corporation5 reports
    $10.2M reported (all issues)
  16. UCB, INC.5 reports
  17. Astellas Pharma US, Inc.4 reports
    $3.1M reported (all issues)Federal contractor: ASTELLAS PHARMA US, INC.AI match · 100%
  18. AstraZeneca Pharmaceuticals LP4 reports
    $3.1M reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  19. BIOTECHNOLOGY INNOVATION ORGANIZATION4 reports
    $6.7M reported (all issues)
  20. GSK (fka GLAXOSMITHKLINE INC.)4 reports
    $4.8M reported (all issues)
  21. National Hemophilia Foundation3 reports
    $150K reported (all issues)
  22. Cigna Corporation2 reports
    $180K reported (all issues)Federal contractor: CIGNA WORLDWIDE INSURANCE BRANCH$2.5M in contracts, FY2026AI match · 99%
  23. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2 reports
    $10.1M reported (all issues)
  24. Rocket Pharmaceuticals, Inc.2 reports
    $60K reported (all issues)
  25. Astellas Gene Therapies, Inc. a Delaware Corporation (fka Audentes Therapeutics)1 report
    $90K reported (all issues)
  26. IONIS PHARMACEUTICALS, INC.1 report
  27. National Bleeding Disorder Foundation (fka National Hemophilia Foundation)1 report
    $50K reported (all issues)
  28. OCHSNER CLINIC FOUNDATION1 report
    $200K reported (all issues)
  29. PFIZER INC.1 report
    $1.1M reported (all issues)Federal contractor: PFIZER INCAI match · 100%
  30. REGENXBIO Inc.1 report
    $91K reported (all issues)

Reports filed in 2023, 2024.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 8, 2026 · loaded Oct 8, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.